- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04043403
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
Deep Brain Stimulation of the subthalamic nucleus (STN) has become a standard of care, FDA-approved treatment for Parkinson's disease, with stimulation delivered at a constant amplitude and voltage, operating in an open-loop fashion that does not respond to a patient's current state. Although gait deficits and freezing of gait may initially respond to continuous open-loop deep brain stimulation (olDBS) and medication, the symptoms often recur over time.
The episodic and predictable nature of FOG makes it well suited for adaptive DBS (aDBS) and a device that overcomes the limitations of traditional high frequency olDBS and is capable of adapting therapy either in the frequency or intensity domain transiently to treat FOG while also treating other PD signs such as tremor and bradykinesia.
The purpose of this study is to determine the feasibility of an adaptive DBS system, that responds to patient-specific neural and kinematic variables with customized DBS parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Helen Bronte-Stewart, MD MSE
- Phone Number: 6507232116
- Email: bronte-stewart-lab@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University
-
Contact:
- Sudeep Aditham
- Phone Number: 650-723-6709
- Email: bronte-stewart-lab@stanford.edu
-
Principal Investigator:
- Helen M Bronte-Stewart, MD MSE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically-established PD
- Meets criteria for STN DBS eligibility as part of patient's standard medical care or already implanted in the STN with Percept(TM) PC
- The presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment in the quality of life on or off medication due to these factors.
- Ability and willingness to return for study visits, at the initial programming and after three, six and twelve months of DBS.
- Age > 18
- Freezing of gait questionnaire (FOG-Q) score ≥ 1 and/or gait sub-score (Item 3.10) of MDS- UPDRS III ≥ 1
- Greater than or equal to 1.2 microVp between 8-35 Hz on either the LSTN or RSTN (Percept (TM) PC cohort only)
Exclusion Criteria:
- Dementia
- Untreated psychiatric disease
- Hoehn and Yahr stage 5 on or off medication (non-ambulatory)
- Age > 80
- Major surgical morbidities such as severe hypertension, coagulopathy and certain metabolic conditions that might increase the risk of hemorrhage or other surgical complications
- Presence of a cardiac pacemaker/defibrillator
- Inability to understand/sign consent
- Requires rTMS, ECT, MRI (Summit(R) RC+S cohort only), or diathermy
- Are pregnant or lactating
- Has a cranial metallic implant
- History of seizures or epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device: Summit RC+S
|
Standard DBS therapy at a constant frequency and voltage
DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
|
Experimental: Device: Percept PC
|
Standard DBS therapy at a constant frequency and voltage
DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to Stimulation Condition
Time Frame: 3 Months
|
A Customized Adverse Events and Tolerability Questionnaire will measure the absence/presence and frequency of paresthesias, and muscle twitching relative to each stimulation condition
|
3 Months
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of life
Time Frame: 3 Months
|
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV will: (I) Evaluate mentation, behavior, and mood (II) Evaluate a patient's activities of daily life (IV) Measure the presence/severity of dyskinesias and other complications of therapy over time |
3 Months
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speech
Time Frame: 6 Months
|
The Speech Intelligibility Test (SIT) will measure changes in speech related to each stimulation condition.
|
6 Months
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gait
Time Frame: 3 Months
|
The Freezing of Gait Questionnaire (FOG-Q) will be used to record changes in gait over time
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Parameters: Arrhythmicity
Time Frame: Collected up to 10 days every 3 months
|
Variability in stride time during a gait task
|
Collected up to 10 days every 3 months
|
Gait Parameters: Mean Shank Angular Velocity
Time Frame: Collected up to 10 days every 3 months
|
Average of the peak shank angular velocities of every stride during the gait task
|
Collected up to 10 days every 3 months
|
Gait Parameters: Mean Gait Cycle Time
Time Frame: Collected up to 10 days every 3 months
|
Average length of time of each stride during a gait task
|
Collected up to 10 days every 3 months
|
Percent Time Freezing
Time Frame: Collected up to 10 days every 3 months
|
The percentage of the gait task was a participant frozen
|
Collected up to 10 days every 3 months
|
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
Time Frame: Collected up to 10 days every 3 months
|
Portion of the scale assesses the motor signs of PD.
Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132.
|
Collected up to 10 days every 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Helen M. Bronte-Stewart, MD,MSE, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 52548
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Open Loop DBS
-
Prasad Shirvalkar, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS); United States...Active, not recruitingChronic Pain | Spinal Cord Injuries | Phantom Limb Pain | Post Stroke PainUnited States
-
Tsinghua UniversityPeking Union Medical College Hospital; Beijing Tiantan Hospital; Beijing Pins... and other collaboratorsRecruiting
-
University of MalayaNot yet recruitingARDS | Ventilator-Induced Lung Injury | Mechanical Ventilation Complication | Ventilator Lung
-
University of Texas at AustinRecruitingMild Cognitive ImpairmentUnited States
-
Stanford UniversityRecruiting
-
University of VirginiaDexCom, Inc.; Insulet Corporation; Abbott Diabetes Care; University of California...CompletedType 1 Diabetes MellitusUnited States
-
MedtronicNeuroCompleted
-
University of VirginiaDexCom, Inc.; Insulet Corporation; Abbott Diabetes Care; University of California...CompletedType 1 Diabetes MellitusUnited States
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
-
University of WashingtonRecruitingSpinal Cord InjuriesUnited States